A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
Crossref DOI link: https://doi.org/10.1186/s13075-016-0981-6
Published Online: 2016-04-02
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yoo, Dae Hyun
Racewicz, Artur
Brzezicki, Jan
Yatsyshyn, Roman
Arteaga, Edgardo Tobias
Baranauskaite, Asta
Abud-Mendoza, Carlos
Navarra, Sandra
Kadinov, Vladimir
Sariego, Irmgadt Goecke
Hong, Seung Suh
Lee, Sung Young
Park, Won
Funding for this research was provided by:
CELLTRION Inc
